$EVEREST MED-B (01952.HK)$According to the announcement, NEFECON (NEFECON) was officially commercialized in mainland China on May 14, 2024, and the first prescription was successfully issued by an Internet hospital. This marks that the world's first drug for IgA nephropathy has officially begun to benefit Chinese patients, opening a new chapter in the treatment of the causes of IgA nephropathy in China.
The company will adopt innovative joint promotion methods between traditional hospitals and internet hospitals, which is expected to greatly enhance the accessibility of patients across the country and improve their medication compliance. Nefukang was approved by China's State Drug Administration in November 2023 to treat adult patients with progressive risk of primary IgA nephropathy.
The results of the NepGard phase III study showed that Tolerant can protect kidney function, delay patients' progression to dialysis or kidney transplantation, significantly reduce urinary protein and hematuria, and is safe and well tolerated. Clinical research data analysis in the Chinese population shows that Nafukang can delay the decline in kidney function by 66% in the Chinese population, delaying the progression of the disease to dialysis or kidney transplantation by 12.8 years. The launch of Nifukang has filled the gap in unmatched treatment of IgA nephropathy in China, benefiting Chinese patients, improving disease prognosis, and bringing new treatment options to clinicians.
Furthermore, the company will work to promote the commercialization process of Nifukang in China and other authorized regions in Asia to benefit more patients.